AGENDA: DUR BOARD MEETING
Health First Colorado, Colorado Medicaid, Drug Utilization Review Board
Department of Health Care Policy and Financing

Skaggs School of Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Blvd, Aurora CO 80045
Seminar Room- Room 1000; First floor
Parking available in the Henderson/Visitor Parking Garage

August 13th, 2019
6:00 p.m. – 9:00 p.m. Open Session
DUR BOARD MEMBERS and CO-DUR MEMBERS

DUR Board Members
Sheila Botts, PharmD (Chair)
Michael Noonan, DO (Vice Chair)
Scott VanEyk, MD
Allison Blackmer, PharmD
Alison Shmerling, MD
Mary Wilkerson, MD
Liza Wilson Claus, PharmD
Gosia Thomas, PharmD
Britt Boehner (Industry Liaison)

CO-DUR Team
Cathy Traugott, RPh, JD (HCPF)
Jeffrey Taylor, PharmD (HCPF)
Robert L Page, PharmD, MSPH (CO DUR)
Brandon Utter, PharmD (CO DUR)
Heather Anderson, PhD (CO DUR)
Garth Wright, MPH (CO DUR)
Gina Moore, PharmD, MBA (CO DUR)

Roll Call / Introductions

Approval of Minutes from May 14th, 2018 Meeting

Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest:
- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Open Session:

Unfinished Business and General Orders:
- Colorado Department of Health Care Policy and Financing Updates
- FDA Updates
Updates on Business from Last Meeting:
(items included in this section are not scheduled for public testimony or board review as part of this agenda)

- Acne Agents:
  - Oral Isotretinoin, Topical
  - Tetracyclines
- Rosacea Agents, Topical (New PDL Class)
- Non-Opioid Analgesics (New PDL Class)
- Opioids –Short-Acting
- Opioids –Long-Acting
- Benign Prostatic Hypertrophy (BPH) Agents (New PDL Class)
- Phosphate Binders (New PDL Class)
- Respiratory Inhalants:
  - Inhaled Anticholinergics & Anticholinergic Combinations
  - Inhaled Beta2Agonists (short-acting)
  - Inhaled Beta2Agonists (long-acting)
  - Inhaled Corticosteroids and Combinations
- Androgenic Agents
- Mass review drug classes:
  - Angiotensin modulators and Angiotensin modulator combinations
    - ACEIs, ACEi Combos
    - ARBs, ARB Combos
    - Renin Inhibitors & Combos
  - Antihistamines, Newer Generation
  - Skeletal Muscle Relaxants
  - Topical Immunomodulators
- Concomitant Utilization of Opioids and Benzodiazepines
- Dupixent (dupilumab)
- Oxandrolone
- Ilumya (tildrakizumab-asmn)
- Infliximab and Biosimilar Products (Remicade, Renflexis, Inflectra)
- Doxepin Topical Formulations (Zonalon, Prudoxin)

New Business (open for public testimony and board review):

Proposed Criteria for PDL Drug Classes Scheduled for Review:

- Diabetes Management Classes –DPP-4 Inhibitors
- Diabetes Management Classes –GLP-1 Analogues
- Diabetes Management Classes –Hypoglycemic Combos
- Diabetes Management Classes –SGLT-2 Inhibitors
- Anticonvulsants
- Colony Stimulating Factors
- Erythropoiesis Stimulating Proteins
- Hereditary Angioedema (HAE) Agents
- Anticoagulants
- Contraceptives, Oral
- GI Motility, Chronic
• Stimulants and Other ADHD Agents
• Mass Review Drug Classes:
  o Bone Resorption Suppression and Related Agents
  o Diabetes Management Classes –Amylin
  o Diabetes Management Classes –Biguanides
  o Diabetes Management Classes –Meglitinides
  o Diabetes Management Classes –TZDs
  o Ophthalmic Immunomodulators
  o Overactive Bladder Agents
  o Prenatal Vitamins

Proposed ProDUR and Prior Authorization Criteria for Other Selected Products:
• Opioid and Benzodiazepine Concomitant Use Criteria
• Opioid and Quetiapine Concomitant Use Criteria
• Proposed Criteria for Selected New PDL Product:
  o Sunosi (solriamfetol)
• Proposed Criteria for Selected Inhaled Antibiotic Products:
  o Tobi Podhaler (tobramycin capsule for inhaler)
  o Arikayse (amikacin suspension)
• Proposed Criteria for Selected Enzyme Replacement Products:
  o Aldurazyme (laronidase)
  o Naglazyme (galsulfase)
• Proposed Criteria for Selected Products Used to Treat Thrombocytopenia:
  o Tavalisse (fostamatinib)
  o Doptelet (avatrombopag)
  o Mulpleta (lusutrombopag)
• Proposed Criteria for Other Selected Products:
  o Glycate (glycopyrollate)
  o Lotemax SM (loteprednol etoabonate ophthalmic gel)
• Review of Products for Proposed Drug Label Prior Authorization:
  o Ruzurgi (amifampridine)
  o Firdapse (amifampridine)
  o Vyndaqel (tafamidis meglumine)
  o Prolia (denosumab) – removed from this meeting agenda

Retrospective DUR Activities:
• Retrospective DUR Updates
• Quarterly Module Summary
• Quarterly Drug Utilization Reports

Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303-866-3105 or jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.